Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Effects of ECMO on the Pharmacokinetics of Hydromorphone
Sponsor: Xiaobo Yang, MD
Summary
The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
26
Start Date
2022-01-01
Completion Date
2024-09-01
Last Updated
2024-08-06
Healthy Volunteers
No
Conditions
Interventions
Hydromorphone
Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.
Locations (1)
Wuhan Union Hospital
Wuhan, Hubei, China